Gemcitabine hydrochloride en es it fr

Gemcitabine hydrochloride Brand names, Gemcitabine hydrochloride Analogs

Gemcitabine hydrochloride Brand Names Mixture

  • No information avaliable

Gemcitabine hydrochloride Chemical_Formula

C9H11F2N3O4

Gemcitabine hydrochloride RX_link

http://www.rxlist.com/cgi/generic/gemcitab.htm

Gemcitabine hydrochloride fda sheet

Gemcitabine_hydrochloride FDA

Gemcitabine hydrochloride msds (material safety sheet)

Gemcitabine_hydrochloride MSDS

Gemcitabine hydrochloride Synthesis Reference

No information avaliable

Gemcitabine hydrochloride Molecular Weight

263.198 g/mol

Gemcitabine hydrochloride Melting Point

168.64oC

Gemcitabine hydrochloride H2O Solubility

Soluble

Gemcitabine hydrochloride State

Solid

Gemcitabine hydrochloride LogP

-1.318

Gemcitabine hydrochloride Dosage Forms

Lyophilized powder for injection

Gemcitabine hydrochloride Indication

For the first-line treatment of patients with metastatic breast cancer, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer and as first-line treatment for patients with adenocarcinoma of the pancreas.

Gemcitabine hydrochloride Pharmacology

Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand.

Gemcitabine hydrochloride Absorption

100%

Gemcitabine hydrochloride side effects and Toxicity

Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD50=500 mg/kg (orally in mice and rats)

Gemcitabine hydrochloride Patient Information

General Patients receiving therapy with Gemzar should be monitored closely by a physician
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next
cycle.

Laboratory Tests Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.

Gemcitabine hydrochloride Organisms Affected

Humans and other mammals